Axinn Obtains Global Antitrust Clearance for Thermo Fisher Scientific Inc.’s $13.6 billion Acquisition
January 31, 2014
Axinn was global coordinating antitrust counsel to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in its $13.6 billion acquisition of Life Technologies Corporation.
Axinn worked with Slaughter & May to help Thermo Fisher secure global clearance across nine different jurisdictions (Federal Trade Commission, European Commission, PRC’s MOFCOM, Canada, Japan, South Korea, Russia, Australia and New Zealand).
The Axinn and Slaughter & May teams successfully navigated nine regulatory reviews of more than fifty (50) different product areas involving complex life science products, which included a Second Request from the Federal Trade Commission and a Phase II investigation from MOFCOM. Axinn and Slaughter & May secured global convergence on remedies through a single US$1 billion divestiture to General Electric Company (as an upfront buyer), tailored to cover only three product areas, and local supply and pricing remedies in China for two additional product areas.
The Axinn team included partners John Harkrider, Michael Keeley, Mark Alexander and Daniel Bitton; counsel Morris Bloom; and associate Daniel Oakes.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
DOJ's Antitrust Division Remains Interested in Your Private Litigation
Byline Articles
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust